Recent Faculty Publications

Our research, which reflects the wide scope of interests encompassed by our division, frequently appears in leading academic journals.

Jad Bou-Abdallah, MD

View full profile

Michael Farrell, M.D.

View full profile

Thomas Mahl, MD

Yang K, Nallapeta N, Hossein-Javaheri N, Carlson A, Quigley B, Mahl T. (2025) Predictors and prognosticators of outcomes in alcoholic hepatitis: A retrospective single center study. World journal of hepatology (Feb), 17(2): 102152. doi:10.4254/wjh.v17.i2.102152
Duve RJ, Moga TG, Yang K, Mahl TC, Dove E. (2023) Hepatic Amyloidosis With Multiorgan Involvement. ACG case reports journal (Apr), 10(4): e00999. doi:10.14309/crj.0000000000000999

View full profile

Anthony Martinez, MD

Sulkowski MS, Martinez A, Tyson GL, Scholz K, Franco RA, Kohli A, Julius SF, Deming P, Fink SA, Lynch K, Roytman M, Stainbrook TR, Turner MD, Viera-Briggs M, Ramers CB. (2024) Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs. Journal of viral hepatitis (Jun), 31(6): 342-356.
Martinez A, Khan T, Dylla DE, Marcinak J, Collins M, Saget B, Conway B. (2023) Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021. Harm reduction journal (Oct), 20(1): 142. doi:10.1186/s12954-023-00874-y
Mukherjee D, Collins M, Dylla DE, Kaur J, Semizarov D, Martinez A, Conway B, Khan T, Mostafa NM. (2023) Assessment of Drug-Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations. Infectious diseases and therapy (Aug), 12(8): 2057-2070. doi:10.1007/s40121-023-00830-0

View full profile

Andrew Talal, MD, MPH

Gonzalez CJ, Perez-Mejia CN, Hernandez N, Kapadia SN, Niederdeppe J, Dharia A, Papalamprakopoulou Z, Talal AH, Lloyd AR, Franco R, Shapiro MF, Wethington E. (2025) Identifying Varying Influences on Eliminating Hepatitis C Across Medical Specialties. Journal of viral hepatitis (Nov), 32(11): e70093.
Talal AH, Markatou M, Zeremski M, Liu A, Dharia A, George SG, Taylor M, Davis K, Silber A, Brown LS, Tobin JN. (2025) Opioid treatment program-integrated facilitated telemedicine for hepatitis C treatment: a hybrid effectiveness-implementation analysis. BMC complementary medicine and therapies (Oct), 25(1): 377.
Papalamprakopoulou Z, Dang TH, Gonzalez CJ, Tedesco CJ, Updike PF, Corl C, Dharia A, Hernandez N, Shapiro MF, Wethington E, Talal AH. (2025) Long-Term Benefits Following Hepatitis C Cure Through Facilitated Telemedicine; Experiences of People With Opioid use Disorder Five Years After Achieving a Sustained Virological Response. Health expectations : an international journal of public participation in health care and health policy (Oct), 28(5): e70404.

View full profile

Nahel Altaf Tunio

View full profile